CAFs orchestrates tumor immune microenvironment-A new target in cancer therapy
Last reviewed: May 17, 2026 Last updated: May 17, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Overexpression of Semaphorin4D indicates poor prognosis and prompts monocyte differentiation toward M2 macrophages in epithelial ovarian cancer
Prolaject B12 1000 Plus Selenium Important Information Find the information you need to incorporate Prolaject B12 1000 Plus Selenium into your cattle and sheep management programme
Oncologist 15 , 360371 (2010)
Many of the symptoms of Graves' disease are directly related to its cause: organ-specific autoimmunity